TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03472170

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral administration of bovine lactoferrin (bLf)
Description: The pharmacy service of the hospital will provide the established dose of lactoferrin, according to the regimen of administration of 150 mg / kg / day (maximum 300 mg / day), as well as that of placebo. Both treatments will be administered in liquid form, in the least amount possible. Both the administration of lactoferrin and placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the newborns with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enteral administration of placebo
Description: Enteral administration of placebo with similar visual and gustatory characteristics in the first 72 hours of life, and for 4 weeks (6 weeks in the RN ≤ 1000 gr and / or EG ≤ 28 weeks).
Study: NCT03828058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus XR
Description: Envarsus XR to be administered orally, once a day. Dosage will be adjusted as determined by trough blood levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Prograf 2 mg BID to be administered orally, twice a day. Dosage will be adjusted as determined by trough blood levels.
Study: NCT05440539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Handouts
Description: The written materials were generated using the collaboration of healthcare communication specialists to generate content that is tailored to a younger age demographic of childbearing age regarding their risk of developing a pelvic floor disorder and what can be done to prevent or treat them in the future.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Handouts
Description: The written materials were generated using the collaboration of healthcare communication specialists to generate content that is tailored to a younger age demographic of childbearing age regarding their risk of developing a pelvic floor disorder and what can be done to prevent or treat them in the future.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Workshop
Description: Participants logged onto a virtual meeting platform and listened to a live 20 minute presentation by a pelvic floor physical therapist followed by time for questions, which were answered live. Participants anonymity was maintained by not allowing participants to view each other's name and disabling sharing of video feeds.
Study: NCT01295372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: 7.5 mg/day; orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 5 mg/day; orally
Study: NCT00659321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine acid
Description: 16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 16 weeks treatment with placebo
Study: NCT01720264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
Study: NCT04699149

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Non-invasive brain stimulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial magnetic stimulation
Description: Non-invasive brain stimulation
Study: NCT04332861

Intervention type: OTHER
Intervention: Initial clinical and laboratory evaluation
Description: Initial evaluation, prior to administration of any antibiotics if possible, includes history, physical exam, and labs including:~* Urinalysis~* Urine culture~* Blood cultures~* Complete blood count with differential~* Comprehensive metabolic panel~* Lactate~* Procalcitonin~* Other inflammatory markers
Study: NCT00006409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial of Activity for Adolescent Girls (TAAG)
Description: Intervention activities were designed to create (1) environmental and organizational changes supportive of physical activity and (2) cues, messages, and incentives to be more active. The intervention was designed to establish more opportunities, improve social support and norms, and increase self-efficacy, outcome expectations, and behavioral skills to foster greater moderate-vigorous physical activity (MVPA). An innovative feature of TAAG was linking school and community agencies to promote activity programs for girls. Finally, a TAAG Program Champion component was developed to foster sustainability after the 2-year staff-directed intervention. TAAG investigators recruited and trained Program Champions during the staff-directed intervention phase to promote maintenance of the program.
Study: NCT00390013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 300 mg. capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~1. day 1 you will take 1 capsule for the day~2. day 2 you will take 1 capsule 2 times for that day~3. days 3-6 you will take 1 capsule 3 times for those days~4. days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~5. days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~6. days 13-14 you will take 2 capsules 3 times each day~7. continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~8. at completion of study treatment you will titrate off study drug over a weeks time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~1. day 1 you will take 1 capsule for the day~2. day 2 you will take 1 capsule 2 times for that day~3. days 3-6 you will take 1 capsule 3 times for those days~4. days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~5. days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~6. days 13-14 you will take 2 capsules 3 times each day~7. continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~8. at completion of study treatment you will titrate off study drug over a weeks time.
Study: NCT02993367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide Soft Capsules
Description: DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.Butylphthalide Soft Capsules is the oral preparation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Butylphthalide Soft Capsules
Study: NCT03048526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaTears®
Description: Topical eye drops for lubrication of the ocular surface

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrabak®
Description: Eye drops
Study: NCT02164448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the dexmedetomidine group
Description: the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: the control group
Description: saline infusion from induction of anesthesia to end of surgery
Study: NCT03401996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 mA tDCS over bilateral SMA
Description: A 1mA direct current will be delivered through two 5cm x 5cm saline-soaked surface sponge electrodes by a battery-driven, constant-current stimulator (Neuroconn DC stimulator). First, the SMA will be identified based on the guidelines of the international 10-20 electrode system. The tDCS will then be applied using the following procedure:~1. The head of participants will be measured to find the 'vertex' (top) of the head. This point will be used as a landmark to locate the SMA. This region corresponds to the FCZ (e.g., Legon et al., 2013).~2. The return electrode will be placed over the mastoids. Once the electrodes are in position, cathodal tDCS will be applied at 1mA for 15 minutes, 2 times a day with a resting period of 20 minutes in between treatment periods, for 5 consecutive days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 1 mA tDCS over bilateral SMA
Description: A 1mA direct current will be delivered through two 5cm x 5cm saline-soaked surface sponge electrodes by a battery-driven, constant-current stimulator (Neuroconn DC stimulator). First, the SMA will be identified based on the guidelines of the international 10-20 electrode system. The tDCS will then be applied using the following procedure:~1. The head of participants will be measured to find the 'vertex' (top) of the head. This point will be used as a landmark to locate the SMA. This region corresponds to the FCZ (e.g., Legon et al., 2013).~2. The return electrode will be placed over the mastoids. Once the electrodes are in position, cathodal tDCS will be applied at 1mA for 15 minutes, 2 times a day with a resting period of 20 minutes in between treatment periods, for 5 consecutive days.
Study: NCT01471093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-12759 Ophthalmic solution
Description: 2％ OPC-12759 Ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-12759 Ophthalmic suspension
Description: 2％ OPC-12759 Ophthalmic suspension
Study: NCT01974648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study: NCT00888745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous and subcutaneous ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO283698
Description: Intravenous and subcutaneous ascending dose
Study: NCT01246284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Injections will be given within a 3 cm2 area of alopecia which will be divided into 4 quadrants. Three different concentrations of triamcinolone acetonide will be used: 2.5, 5, and 10 mg/ml. Each quadrant will receive injections with either triamcinolone acetonide 2.5 mg/ml, triamcinolone acetonide 5 mg/ml, triamcinolone acetonide 10 mg/ml, or normal saline as a control. Injection of 0.1 ml will be given intradermally using a 30 gauge half inch long needle attached to a 3 ml syringe. Each quadrant will receive approximately 7 injections per treatment session so the total dose of triamcinolone acetonide will be around 13 mg. Injections will be given vertically, with the beveled side of the needle directed to the opposite side and 2 mm away from the margin of the adjacent quadrant to avoid a diffusion effect. The treatment will be repeated every 4 to 6 weeks for a total of 6 treatment sessions.
Study: NCT01974648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol and remifentanil
Study: NCT03142360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (Berasil)
Description: Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
Study: NCT01965522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (melatonin)
Description: Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (melatonin)
Description: Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (vitamin D)
Description: Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vitamin D)
Description: Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.
Study: NCT03916497

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantiferon CMV
Description: Evaluate and compare interferon gamma (IFNy) production by T CD8 cells exposed to CMV antigens in CMV seropositive kidney transplant recipients, hemodialysis and control patients
Study: NCT01246284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Injections will be given within a 3 cm2 area of alopecia which will be divided into 4 quadrants. Three different concentrations of triamcinolone acetonide will be used: 2.5, 5, and 10 mg/ml. Each quadrant will receive injections with either triamcinolone acetonide 2.5 mg/ml, triamcinolone acetonide 5 mg/ml, triamcinolone acetonide 10 mg/ml, or normal saline as a control. Injection of 0.1 ml will be given intradermally using a 30 gauge half inch long needle attached to a 3 ml syringe. Each quadrant will receive approximately 7 injections per treatment session so the total dose of triamcinolone acetonide will be around 13 mg. Injections will be given vertically, with the beveled side of the needle directed to the opposite side and 2 mm away from the margin of the adjacent quadrant to avoid a diffusion effect. The treatment will be repeated every 4 to 6 weeks for a total of 6 treatment sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Injections will be given within a 3 cm2 area of alopecia which will be divided into 4 quadrants. Three different concentrations of triamcinolone acetonide will be used: 2.5, 5, and 10 mg/ml. Each quadrant will receive injections with either triamcinolone acetonide 2.5 mg/ml, triamcinolone acetonide 5 mg/ml, triamcinolone acetonide 10 mg/ml, or normal saline as a control. Injection of 0.1 ml will be given intradermally using a 30 gauge half inch long needle attached to a 3 ml syringe. Each quadrant will receive approximately 7 injections per treatment session so the total dose of triamcinolone acetonide will be around 13 mg. Injections will be given vertically, with the beveled side of the needle directed to the opposite side and 2 mm away from the margin of the adjacent quadrant to avoid a diffusion effect. The treatment will be repeated every 4 to 6 weeks for a total of 6 treatment sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT01211249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259 oral capsule
Description: Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)
Study: NCT03916497

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantiferon CMV
Description: Evaluate and compare interferon gamma (IFNy) production by T CD8 cells exposed to CMV antigens in CMV seropositive kidney transplant recipients, hemodialysis and control patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantiferon CMV
Description: Evaluate and compare interferon gamma (IFNy) production by T CD8 cells exposed to CMV antigens in CMV seropositive kidney transplant recipients, hemodialysis and control patients
Study: NCT00614952

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PSG (polysomnography)
Description: POLYSOMNOGRAPHY

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PR (respiratory polygraphy)
Description: respiratory polygraphy: level III of AASM
Study: NCT01159132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: 12 hour PK will be done on day 1 while subjects is on stable regimen with RAL 400 mg BID. After performing intensive PK, subjects will be randomized to either group A (RAL 400 mg OD) or B (RAL 800 mg OD) for 14 days and on day 15, a second 24 hour full PK will be carried out. After the intensive PK, subjects in both the groups will switched to the other dosing regimen, group A (RAL 800 mg OD) and B (RAL 400 mg OD) for another 14 days and on day 29, the third 24 hour full PK will be carried out.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: 12 hour PK will be done on day 1 while subjects is on stable regimen with RAL 400 mg BID. After performing intensive PK, subjects will be randomized to either group A (RAL 400 mg OD) or B (RAL 800 mg OD) for 14 days and on day 15, a second 24 hour full PK will be carried out. After the intensive PK, subjects in both the groups will switched to the other dosing regimen, group A (RAL 800 mg OD) and B (RAL 400 mg OD) for another 14 days and on day 29, the third 24 hour full PK will be carried out.
Study: NCT02461771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.
Study: NCT01763385

Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: RADIATION
Group type: OTHER
Intervention: concurrent brain radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: secondary brain radiotherapy
Study: NCT04058288

Intervention type: DEVICE
Intervention: High-definition Transcranial Direct Current Stimulation
Description: Stimulation sessions will be conducted on 2 different visits separated by 2-week gap. In a crossover design, Anodal HD-tDCS will be delivered either in Active/Sham mode (during the first visit) and Sham/Active during the second visit in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
Study: NCT01661686

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Partially covered SEMS
Description: Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fully covered SEMS
Description: Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
Study: NCT04645615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioblate surgical ablation system
Description: This investigation is a prospective, non-randomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical RF Ablation
Description: This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
Study: NCT03649841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiandrogen Therapy
Description: Undergo ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Undergo ADT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Undergo Abiraterone Acetate Treatment SOC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Undergo Abiraterone Acetate Treatment SOC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Undergo Prednisone Treatment SOC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Undergo Prednisone Treatment SOC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo neutron radiation therapy
Study: NCT03687515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: 1mg/2ml Pulmicort Respules BIS twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: nasal spray 256μg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: oral prednisone 24mg QD
Study: NCT01390844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Description: 200 mg capsules, 800 mg three times daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to boceprevir
Description: 200 mg placebo capsules, 800 mg three times daily by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to boceprevir
Description: 200 mg placebo capsules, 800 mg three times daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (PEG)
Description: 1.5 mcg/kg/week subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2b (PEG)
Description: 1.5 mcg/kg/week subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200 mg capsules, weight-based dosing 800 to 1400 mg/day by mouth divided twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin (RBV)
Description: 200 mg capsules, weight-based dosing 800 to 1400 mg/day by mouth divided twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cross-Over Boceprevir Treatment
Description: At Treatment Week 14, participants in the Placebo group with detectable HCV-RNA at Treatment Week 12 have the option to add boceprevir 800 mg three times daily to the PEG + RBV regimen for up to 32 weeks.